On January 15, Takara Bio USA Holdings Inc., a wholly owned subsidiary of Takara Bio Inc., announced that it acquired Curio Bioscience.
Curio Bioscience is a biotechnology company that is advancing a new generation of high-precision tools for the life sciences industry. The company has developed spatial biology capabilities to map the whole transcriptome at high resolution using existing sequencing workflows and instrumentation.
Takara Bio USA Holdings Inc. manufactures and distributes kits, reagents and instruments for the life sciences, including next-generation sequencing, gene delivery, genome editing, stem cell research, nucleic acid and protein purification and automated sample preparation. It does all this under the Takara®, Clontech® and Cellartis® Brands.
The Curio Bioscience acquisition will extend the power of Takara Bio’s sequencing solutions and give customers deeper insights into tissue spatial organization and molecular composition.
Houlihan Lokey acted as exclusive financial advisor and Cooley LLP acted as legal advisor to Takara Bio. Aquilo Partners, L.P. acted as financial advisor and Dorsey & Whitney LLP as legal advisor to Curio Bioscience.
According to data in the LevinPro HC database, this marks the 14th Biotechnology transaction of 2025. Throughout 2024, there were 135 Biotechnology transactions announced. This is also Takara Bio’s first acquisition of the year.
